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Figure 1: Structure of methylglyoxal. 
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Conclusions
We found that higher doses of methylglyoxal reduced cell viability in a dose- dependent manner which may be 
related to increased levels of ROS within the cell.  However, when methylglyoxal was introduced with 
metformin, aminoguanidine hydrochloride, or pyridoxamine dihydrochloride, cell viability was significantly 
improved (p <0.05 ). Meanwhile, higher intracellular ROS caused by methylglyoxal was significantly 
decreased in the presence of metformin or aminoguanidine dihydrochloride. Future studies will investigate 
mitochondrial function and the possible mechanisms underlying the effects of methylglyoxal, metformin and 
aminoguanidine hydrochloride.
Figure 9: (A) Metformin showed a significant dose dependent reduction of ROS in H9C2 cells after 24 hours of 
incubation with methylglyoxal (n=3, *: p < 0.05 vs. control). (B) Aminoguanidine hydrochloride illustrated 
ROS reduction in higher doses after 24 hours when treated concurrently with methylglyoxal (n=3, *: p < 0.05 
vs. control). Both metformin and aminoguanidine hydrochloride indicate significant protective effects against 
methylglyoxal- induced ROS. 
Figure 5: Higher doses of methylglyoxal (800 µM-2000 µM) significantly reduced viability in H9C2 
myoblasts when compared to the control (n=4, *: p < 0.05 vs. control).
Results
Figure 7: High doses of metformin , aminoguanidine hydrochloride and pyridoxamine dihydrochloride 
showed significant protection against methylglyoxal-induced cell death ( n=7, *: p < 0.05 vs methylglyoxal). 
Introduction
Hypothesis
Methods
We hypothesized that methylglyoxal reduced viability of H9C2 myoblast cells in a dose-dependent manner by 
increasing free radicals.  By contrast, concurrently treated with both methylglyoxal and either metformin, 
aminoguanidine hydrochloride, or pyridoxamine dihydrochloride would increase cell viability accompanied 
with reduction of free radicals . 
Measurement of cell viability: H9C2 rat myoblasts were seeded at 2x104 cells per well 24 hours prior to 
experiment. For testing the dose-response of methylglyoxal, cells were treated with varying concentrations 
(400 µM- 2000 µM) of methylglyoxal and incubated for 24 hours before analysis. To determine the protective 
effects, cells were treated with metformin (1-40 mM), aminoguanidine hydrochloride (250 µM- 2000 µM) and 
pyridoxamine dihydrochloride (0.1 µM - 15µM)  in presence of methylglyoxal (1200 µM) and monitored for 
dose dependent effects after 24 hours. Cell viability was assessed using CCK-8 assay (Dojindo Molecular 
Technologies) after washing out all the compounds from medium.  Moreover, cell morphology was observed 
using microscopy.  Cell viability was expressed as the ratio of CCK readings to the non-treated control. 
Measurement of intracellular ROS by DCFDA: After H9C2 rat myoblasts were seeded for 24 hours, cell 
media were replaced with 20 μM non-fluorescent dichlorofluorescein diacetate (DCFDA, Abcam) for 45 
minutes to allow the dye to load into the cell. After washing out the unloaded DCFDA, the cells were 
incubated with media containing 1200 µM methylglyoxal with metformin (1-40mM) or aminoguanidine 
hydrochloride (250µm-8000µm).  Inside the cell, DCFDA was deacetylated by cellular esterases to a non-
fluorescent compound, which is later oxidized by ROS into a highly fluorescent compound2’, 7’ –
dichlorofluorescein (DCF). At 1 hour, 24 hours and >36 hours after treatment, fluorescence was measured at 
excitation ( 488 nm) and emission (527 nm) using a Fluroskan Ascent CF scanner (Thermo scientific). The 
change of ROS was expressed as the ratio to the baseline of non-treated control cells.
Statistical Analysis: All experiments were performed in triplicate and repeated at least three times. All values 
are presented as a mean ± SE. The significance was examined by ANOVA Fischer’s PLSD. Values of p < 0.05 
were considered statistically significant. 
Figure 8: Representative microscopy of H9C2 cells (10X) under control, methylglyoxal 1200 µM, metformin 
40 mM + methylglyoxal 1200 µM and aminoguanidine hydrochloride 8000 µM + methylglyoxal 1200 µM.
Figure 6: At 24 hours, higher doses of methylglyoxal (800 µM-2000 µM) showed significantly increased 
levels of ROS production compared to the control (n=3, *: p < 0.05 vs. control). 
Figure 2: Structure of metformin.
Cardiovascular disease is one of the many complications that can arise from diabetes1. Diabetic patients may 
undergo two main cellular changes regardless if glucose concentrations are properly maintained: advanced 
glycation of end (AGE) products and overwhelming oxidative stress within the cell. Although low levels of 
AGE  are found normally at a basal level within the blood, diabetics have shown to have an increased level that 
may lead to atherosclerosis in vasculature2. 
Methylglyoxal, a byproduct of glucose metabolism, has been shown to be 
elevated in the blood of diabetic patients and has been identified as an 
intermediate in the production of advanced glycation end products.  Due to its 
structure, methylglyoxal is highly reactive with a wide range of  cellular 
components. Specifically in the formation of AGEs, methylglyoxal modifies a 
select few amino acids and leads to final production of AGEs. The 
accumulation of these AGEs can cause inflammation, oxidative stress and cell 
death3. Similarly, methylglyoxal is able to produce high levels of reactive 
oxygen species (ROS) within the cell via mitochondrial modification which 
results in a loss of membrane potential and an increase in intracellular calcium concentrations. High levels of 
ROS are damaging to the cell and can lead to alteration in gene expression, inflammatory responses, structural 
changes, and cell death4. The effects and  mechanism of methylglyoxal have not been fully elucidated. 
In order to reverse the effects of methylglyoxal, our study tests three compounds that have either been utilized 
in the treatment of diabetes or have been shown to decrease the amount of AGEs in the cell. Metformin, a 
common management medication for diabetics, works by lowering the level of endogenous methylglyoxal in 
the body, thus decreasing the quantity of AGEs produced and lessening the production of ROS5. 
Aminoguanidine hydrochloride and pyridoxamine dihydrochloride act to reduce levels of AGEs by inhibiting 
one of the intermediate steps, therefore decreasing the effects of AGEs and decreasing the amount of ROS as 
well6,7. Metformin, aminoguanidine hydrochloride, and pyridoxamine dihydrochloride utilize different 
mechanisms that interfere with the development of AGEs in the body, but these protective properties have not 
been tested with respect to cardiomyocytes.
In this study we compared the effects of metformin, aminoguanidine hydrochloride, or pyridoxamine 
dihydrochloride on methylglyoxal-induced cell damage and ROS production in H9C2 myoblast cells. 
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Figure 4: Structure of pyridoxamine 
dihydrochloride. 
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Figure 3: Structure of aminoguanidine 
hydrochloride.
